QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC

This report aimed to provide the full results of QoL assessment in INFORM study. QoL was assessed by FACT-L questionnaire. QoL improvement ratio in gefitinib arm was higher than placebo arm (FACT-L: 46% vs. 22%, p < 0.001; TOI: 41% vs. 18%, p < 0.001; LCS: 46% vs. 22%, p < 0.001). Gefitinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yun-Peng, Ma, Yu-Xiang, Huang, Yan, Zhao, Yuan-Yuan, Fang, Wen-Feng, Hong, Shao-Dong, Tian, Ying, Xue, Cong, Sheng, Jin, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490396/
https://www.ncbi.nlm.nih.gov/pubmed/26137916
http://dx.doi.org/10.1038/srep11934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490396/
https://www.ncbi.nlm.nih.gov/pubmed/26137916
http://dx.doi.org/10.1038/srep11934

Ejemplares similares